替吉奥胶囊单药治疗晚期胃癌的临床观察  

Clinical Observation of S1 Capsule for Advanced Gastric Cancer

作　　者：李志玖[1] 艾淑颖[1] 宋先波 

机构地区：[1]湖北医药学院附属太和医院肿瘤科,442000 [2]十堰市医药卫生学校,442000

出　　处：《实用癌症杂志》2013年第1期56-57,共2页The Practical Journal of Cancer

摘　　要：目的探讨替吉奥胶囊单药治疗晚期胃癌的疗效与不良反应。方法 2009年1月～2011年1月,22例晚期胃癌患者采用口服替吉奥胶囊60 mg/次,一日2次,连续2周停1周,3周重复,连用2周期。按RECIST1.1标准评价客观疗效和不良反应。结果 22例患者中CR 0例,PR 12例(54.5%),SD 9例(40.9%),PD 1例(4.5%),总有效率为54.5%。不良反应主要是血液学毒性、胃肠道反应,且均为Ⅰ～Ⅱ度。结论替吉奥胶囊单药治疗晚期胃癌近期疗效较好,不良反应可以耐受,对晚期胃癌患者,特别是年龄较大、一般状态较差的患者是安全有效的。Objective To evaluate the efficacy and adverse effect of S-1 capsule on advanced gastric cancer.Methods A total of 22 patients with advanced gastric cancer were selected from January 2009 to January 2011.All enrolled patients received S-1,60mg,bid.The treatment lasted for 2 weeks followed by 1 week interval.The protocol was repeated every 3 weeks.All of the patients underwent the treatment for two cycles.Efficacy and toxicities were evaluated according to the RECIST1.1 standard.Results Of the 22 patients,CR was in 0,PR was in 12（54.5%）,SD was in 9（40.9%） and PD was in 1（4.5%）,The total response rate was 54.5%.The major toxic reactions were hematological and digestive toxic reactions.Conclusion S-1 single-drug regimen achieved relatively satisfactory short-term efficacy in the treatment of advanced gastric cancer especially for old patients.

关 键 词：替吉奥胶囊 晚期胃癌 

分 类 号：R735.2[医药卫生—肿瘤]